Call it the scientist’s version of happy hour: A new, four-drug cocktail has shown a novel ability to reverse established Type 1 diabetes in some mice, University of Florida Health researchers have found.
Randomized cross-over design (11 days bionic pancreas, 11 days usual care)Subjects work or study on one of four campusesMGH, UNC Chapel Hill, Stanford, UMass Medical Center10 subjects per site (40 total)Normal daily routine, no restrictions on diet or exerciseRemote monitoring of alarms in BP, call subject if not response to alarms
Ellen H Ullman, MSW's insight:
Thank you Joshua Levy for sharing this via Twitter
Among treatments for chronic conditions, diabetes drugs aren't nearly as sexy as, say, Sovaldi, last year's breakthrough hepatitis C drug that offers a cure for the chronic liver infection at a price approaching six figures.
Insulet said its long-troubled Billerica, MA manufacturing plant is back on track on an earnings call earlier this month--just before the FDA offered details on the OmniPod recalls that were caused by inadequate standards compliance.
A new technique to produce cells with insulin-secretion capabilities has been developed, according to research presented today at the 54th Annual European Society for Paediatric Endocrinology Meeting. The technique could be further developed to be used in the transplantation for patients with type 1 diabetes.
Emergency physicians should consider switching from D50W to the safer, less error-prone, equally effective D10W when treating hypoglycemia. “An amp of D50” – 25 grams of glucose in a 50 mlprefilled syringe (50% glucose) – is, and has been since at least the middle of the last century, a standard parenteral treatment by U.S. emergency physiciansRead More
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and added some color.
Ellen H Ullman, MSW's insight:
Zosano Pharma Corp. (NASDAQ: ZSAN) recently completed its enrollment for the Phase 2 trial for ZP-Glucagon. If it is approved by the FDA, it has the potential to be a significant improvement over the currently marketed products for treatment of severe hypoglycemia, which often require a lay person to deliver an injection after a cumbersome preparation process. The company anticipates announcing top-line data from the trial around September. Shares of Zosano ended the week at $8.10, in its 52-week range of $7.01 to $12.40. The consensus analyst price target is $21.00.
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.